Contents

Search

tafamidis; tafamidis meglumine (Vyndaqel. Vyndamax)

Indications: - transthyretin cardiac amyloidosis Dosage: - 20-80 mg QD Mechanism of action: - tafamidis binds to transthyretin & stabilizes it, & inhibits its deposition as amyloid - lowers all-cause mortality (30% vs 43%, RR=0.70) - lessened decline in 6-minute walk test

Related

transthyretin cardiac amyloidosis; amyloid transthyretin cardiomyopathy (ATTR-CM)

General

metabolic agent (metabolic modifier) heterocyclic compound, 2 rings

Database Correlations

PUBCHEM correlations

References

  1. Maurer MS, Schwartz JH, Gundapaneni B et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018 Aug 27; PMID: 30145929 Free full text https://www.nejm.org/doi/10.1056/NEJMoa1805689 - Quarta CC, Solomon SD. Stabilizing transthyretin to treat ATTR cardiomyopathy. N Engl J Med 2018 Aug 27 PMID: 30145933 Free Article https://www.nejm.org/doi/10.1056/NEJMe1810074